REGENERON PHARMACEUTICALS, INC. Revenue From Contract With Customer Excluding Assessed Tax

• REGENERON PHARMACEUTICALS, INC. showed an increase of +1.0% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
• This data is from REGENERON PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 4, 2026.
• XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2017: $1.32 billion | Q2 2017: $1.47 billion | Q3 2017: $1.50 billion | Q4 2017: $1.58 billion | Q1 2018: $1.51 billion | Q2 2018: $1.61 billion | Q3 2018: $1.66 billion | Q4 2018: $1.93 billion | Q1 2019: $1.37 billion | Q2 2019: $1.58 billion | Q3 2019: $1.74 billion | Q4 2019: $1.86 billion | Q1 2020: $1.83 billion | Q2 2020: $1.95 billion | Q3 2020: $2.29 billion | Q4 2020: $2.42 billion | Q1 2021: $2.53 billion | Q2 2021: $5.14 billion | Q3 2021: $3.45 billion | Q1 2022: $2.97 billion | Q2 2022: $2.86 billion | Q3 2022: $2.94 billion | Q1 2023: $3.16 billion | Q2 2023: $3.16 billion | Q3 2023: $3.36 billion | Q1 2024: $3.15 billion | Q2 2024: $3.55 billion | Q3 2024: $3.72 billion | Q1 2025: $3.03 billion | Q2 2025: $3.68 billion | Q3 2025: $3.75 billion.
• Over the full 10 years of available data (2016 to 2025), REGENERON PHARMACEUTICALS, INC.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 195.1%.
• Historical annual values: Fiscal year 2025: $14.34 billion | Fiscal year 2024: $14.20 billion | Fiscal year 2023: $13.12 billion | Fiscal year 2022: $12.17 billion | Fiscal year 2021: $16.07 billion | Fiscal year 2020: $8.50 billion | Fiscal year 2019: $6.56 billion | Fiscal year 2018: $5.15 billion | Fiscal year 2017: $5.87 billion | Fiscal year 2016: $4.86 billion.
• Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: August 9, 2026